Epeius Biotechnologies announced that the FDA has granted fast track designation to Rexin-G for use as a second-line treatment for advanced or metastatic pancreatic cancer. The Fast Track Product designation is granted following a critical evaluation of the life-threatening nature of an unmet medical need, namely pancreatic cancer, and the potential of Rexin-G and its progressive clinical development to address this unmet need.

Rexin-G is a first-in class of new tumor-targeted genetic anti-cancer agents designed to deliver a tumor-killing designer gene to selectively destroy tumor cells and their attendant blood supply, while sparing normal cells and healthy tissues.

For more information call (626) 441-6695 or visit www.epeiusbiotech.com.